NHG-Richtlijnen
NHG-Standaard
M48
3.0
januari 2018
januari 2018
R. Luchtwegen

Begrippen

Naar Volledige tekst ›

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Consultatie en verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Buiten de scope

Naar Samenvatting ›

Samenwerking

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Allergische rinitis

Naar Samenvatting ›

Niet-allergische rinitis

Naar Samenvatting ›

Orale-allergiesyndroom

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Incidentie en prevalentie

Naar Samenvatting ›

Onderrapportage

Naar Samenvatting ›

Beloop

Naar Samenvatting ›

Risicofactor voor astma

Naar Samenvatting ›

Kinderen

Naar Samenvatting ›

Pathofysiologie

Naar Samenvatting ›

Allergische rinitis

Naar Samenvatting ›
Vroegefasereactie
Naar Samenvatting ›
Latefasereactie
Naar Samenvatting ›
Hyperreactiviteit en priming
Naar Samenvatting ›
Belangrijkste allergenen
Naar Samenvatting ›

Niet-allergische rinitis

Naar Samenvatting ›
Belangrijkste subtypen
Naar Samenvatting ›
Hyperreactiviteit
Naar Samenvatting ›

Overige diagnoses

Naar Samenvatting ›

Sinusgerelateerde aandoeningen

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Klachten

Naar Samenvatting ›

Ontstaan en verergering van klachten

Naar Samenvatting ›

Overig

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Andere oorzaken uitsluiten

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›
Graspollen- of boompollenallergie
Naar Samenvatting ›
Bloedonderzoek op inhalatieallergenen
Naar Samenvatting ›
Specifieke IgE-bepaling
Naar Samenvatting ›
Allergeenspecifieke IgE-bepaling
Naar Samenvatting ›
Concentratiespecifieke IgE-bepaling
Naar Samenvatting ›
Beoordeling in context van klachten
Naar Samenvatting ›
Huispriktest versus allergeenspecifieke IgE-bepaling
Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Allergische rinitis

Naar Samenvatting ›

Niet-allergische rinitis

Naar Samenvatting ›

Werkgerelateerde rinitis

Naar Samenvatting ›

Richtlijnen beleid allergische rinitis

Naar Samenvatting ›

Voorlichting

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

Prikkels vermijden en stoppen met roken

Naar Samenvatting ›

Neusdruppels met fysiologisch zout

Naar Samenvatting ›

Pollenallergie

Naar Samenvatting ›

Huisstofmijtallergie

Naar Samenvatting ›

Allergie voor huisdieren

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Keuze medicamenteuze behandeling

Naar Samenvatting ›

Oudere sederende antihistaminica

Naar Samenvatting ›

Keuze geneesmiddel

Naar Samenvatting ›
Voorkeursmiddelen
Naar Samenvatting ›
Voorlichting
Naar Samenvatting ›

Allergische oogklachten

Naar Samenvatting ›

Kortademigheid en piepen

Naar Samenvatting ›

Zwangerschap en borstvoeding

Naar Samenvatting ›
Neusspray en systemische behandeling
Naar Samenvatting ›

Bijwerkingen

Naar Samenvatting ›

Kinderen

Naar Samenvatting ›

Overige medicatie bij allergische rinitis

Naar Samenvatting ›
Cromoglicinezuur
Naar Samenvatting ›
Montelukast
Naar Samenvatting ›
Oraal of intramusculair toegediende corticosteroïden
Naar Samenvatting ›
Sublinguale immunotherapie
Naar Samenvatting ›
Subcutane immunotherapie
Naar Samenvatting ›
Subcutane immunotherapie
Naar Samenvatting ›
Medicamenteuze behandeling anafylaxie bij volwassenen
Naar Samenvatting ›

Controle

Naar Samenvatting ›
Combinatiepreparaat (azelastine/fluticason)
Naar Samenvatting ›

Richtlijnen beleid niet-allergische rinitis

Naar Samenvatting ›

Voorlichting

Naar Samenvatting ›

Medicamenteuze rinitis

Naar Samenvatting ›

Rinitis door decongestiva

Naar Samenvatting ›
Corticosteroïdneusspray bij rinitis door decongestiva
Naar Samenvatting ›

Rinitis door geneesmiddelen

Naar Samenvatting ›

Overige oorzaken

Naar Samenvatting ›
Idiopathische rinitis: azelastineneusspray
Naar Samenvatting ›
Idiopathische rinitis: nasale corticosteroïden
Naar Samenvatting ›
Idiopathische rinitis: ipratropiumbromide
Naar Samenvatting ›
Rinitis bij ouderen
Naar Samenvatting ›
Rinitis door roken
Naar Samenvatting ›
Rinitis door zwangerschap
Naar Samenvatting ›
Conchahypertrofie
Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Kno-arts

Naar Samenvatting ›
Operatieve behandeling
Naar Samenvatting ›

Kno-arts, allergoloog of kinderallergoloog/-arts

Naar Samenvatting ›

Allergoloog

Naar Samenvatting ›

Bedrijfsarts

Naar Samenvatting ›

Referenties

  1. Chivato T, Valovirta E, Dahl R, De Monchy J, Bloch Thomsen A, Palkonen S, et al. Allergy, living and learning: diagnosis and treatment of allergic respiratory diseases in Europe. J Investig Allergol Clin Immunol 2012;22:168-79.
  2. Fromer LM, Blaiss MS, Jacob-Nara JA, Long RM, Mannion KM, Lauersen LA. Current allergic rhinitis experiences survey (cares): consumers’ awareness, attitudes and practices. Allergy Asthma Proc 2014;35:307-15.
  3. Fromer LM, Ortiz G, Ryan SF, Stoloff SW. Insights on allergic rhinitis from the patient perspective. J Fam Pract 2012;61:S16-22.
  4. Naclerio RM, Hadley JA, Stoloff S, Nelson HS. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 2007;28 Suppl 1:S11-7.
  5. Ciprandi G, De Amici M, Marseglia G. Comparison of serum specific ige and skin prick test in polysensitized children. Clin Lab 2011;57:83-5.
  6. Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc 2003;24:231-8.
  7. Meltzer EO. Allergic rhinitis: the impact of discordant perspectives of patient and physician on treatment decisions. Clin Ther 2007;29:1428-40.
  8. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108:S147-S334.
  9. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic rhinitis and its impact on asthma (aria): achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049-62.
  10. NIVEL. Linh-zorgregistratie huisartsen (2014). Incidentie- en preva- lentiecijfers in de huisartsenpraktijk. Ga naar bron
  11. Blomme K, Tomassen P, Lapeere H, Huvenne W, Bonny M, Acke F, et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. Int Arch Allergy Immunol 2013;160:200-7.
  12. Gronhoj Larsen C, Gyldenlove M, Linneberg A. Allergic rhinitis is often undiagnosed and untreated: results from a general population study of danish adults. Clin Respir J 2013;7:354-8.
  13. Greisner WA, III, Settipane RJ, Settipane GA. Natural history of hay fever: a 23-year follow-up of college students. Allergy Asthma Proc 1998b;19:271-5.
  14. Bodtger U, Linneberg A. Remission of allergic rhinitis: an 8-year observational study. J Allergy Clin Immunol. 2004;114:1384-8.
  15. Passali GC, Bellussi LM, De Corso E, Passali FM, Passali D. The natural course of allergic rhinitis: a 32-year follow-up study. Acta Otolaryngol 2013;133:1188-95.
  16. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106:S20b1-S5.
  17. Greisner WA, III, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998a;19:185-8.
  18. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002;109:419-25.
  19. Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999;103:54-9.
  20. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, et al. Common characteristics of upper and lower airways in rhinitis and asthma: aria update, in collaboration with ga(2)len. Allergy 2007;62 Suppl 84:1-41.
  21. Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjan A, McEuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med 2001;164:858-65.
  22. Corren J, Manning BE, Thompson SF, Hennessy S, Strom BL. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004;113:415-9.
  23. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998;101:S352-6.
  24. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy 2013;68:569-79.
  25. Baatenburg De Jong AB, Te Rijdt JP, Brand PL. Hoesten en malaise bij jonge kinderen, ten gevolge van allergische rinoconjunctivitis. Ned Tijdschr Geneeskd 2005;149:1545-8.
  26. Van Velzen MF, Roorda RJ, Brand PL. Allergieonderzoek bij recidiverend hoesten en piepen ook bij kinderen jonger dan 4 jaar mogelijk zinvol. Ned Tijdschr Geneeskd 2004;148:888-91.
  27. Bachert C, Vignola AM, Gevaert P, Leynaert B, Van Cauwenberge P, Bousquet J. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004;24:19-43.
  28. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. American academy of allergy, asthma, and immunology. Ann Allergy Asthma Immunol 1998;81:478-518.
  29. Segboer CL, Holland CT, Reinartz SM, Terreehorst I, Gevorgyan A, Hellings PW, et al. Nasal hyper-reactivity is a common feature in both allergic and nonallergic rhinitis. Allergy 2013;68:1427-34.
  30. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:S2-8.
  31. Kalra S, Crank P, Hepworth J, Pickering CA, Woodcock AA. Absence of seasonal variation in concentrations of the house dust mite allergen Der p1 in South Manchester homes. Thorax 1992;47:928-31.
  32. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med 2005;4:21-9.
  33. Graf P, Hallen H. One-week use of oxymetazoline nasal spray in patients with rhinitis medicamentosa 1 year after treatment. ORL J Otorhinolaryngol Relat Spec 1997;59:39-44.
  34. Garay R. Mechanisms of vasomotor rhinitis. Allergy 2004;59 Suppl 76:4-9.
  35. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22.
  36. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. Aiane investigators. European network on aspirin-induced asthma. Eur Respir J 2000;16:432-6.
  37. Ellegard E, Hellgren M, Toren K, Karlsson G. The incidence of pregnancy rhinitis. Gynecol Obstet Invest 2000;49:98-101.
  38. Johansson L, Akerlund A, Holmberg K, Melen I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol 2003;112:625-9.
  39. Gendo K, Larson EB. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med 2004;140:278-89.
  40. Demir O, Roder R, Berger M. Kan een patient met klachten van graspollenallergie zonder voorafgaande tests behandeld worden? Huisarts Wet 2005;48:655-60.
  41. Larsen K, Tos M. The estimated incidence of symptomatic nasal polyps. Acta Otolaryngol 2002;122:179-82.
  42. Olivieri M, Heinrich J, Schlunssen V, Anto JM, Forsberg B, Janson C, et al. The risk of respiratory symptoms on allergen exposure increases with increasing specific ige levels. Allergy 2016;71:859-68.
  43. Smith HE, Hogger C, Lallemant C, Crook D, Frew AJ. Is structured allergy history sufficient when assessing patients with asthma and rhinitis in general practice? J Allergy Clin Immunol 2009;123:646-50.
  44. Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test - European standards. Clin Transl Allergy 2013;3:3.
  45. Lin MS, Tanner E, Lynn J, Friday GA, Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993;71:557-62.
  46. Ten RM, Klein JS, Frigas E. Allergy skin testing. Mayo Clin Proc 1995;70:783-4.
  47. Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy 2012;26:e119-25.
  48. Li H, Sha Q, Zuo K, Jiang H, Cheng L, Shi J, et al. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. ORL J Otorhinolaryngol Relat Spec 2009;71:50-5.
  49. Chen JR, Jin L, Li XY. The effectiveness of nasal saline irrigation (seawater) in treatment of allergic rhinitis in children. Int J Pediatr Otorhinolaryngol 2014;78:1115-8.
  50. Xiong M, Fu X, Deng W, Lai H, Yang C. Tap water nasal irrigation in adults with seasonal allergic rhinitis: a randomized double-blind study. Eur Arch Otorhinolaryngol 2014;271:1549-52.
  51. Sheikh A, Hurwitz B, Nurmatov U, Van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010:Cd001563.
  52. Gotzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008:Cd001187.
  53. Shirai T, Matsui T, Suzuki K, Chida K. Effect of pet removal on pet allergic asthma. Chest 2005;127:1565-71.
  54. Kilburn S, Lasserson TJ, McKean M. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev 2001:Cd002989.
  55. Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis--a systematic review of randomized controlled trials. Clin Exp Allergy 2005;35:207-12.
  56. Lee TA, Pickard AS. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 2007;27:852-9.
  57. Han D, Chen L, Cheng L, Liu S, Fu Z, Zhang W, et al. A multicenter randomized double-blind 2-week comparison study of azelastine nasal spray 0.1% versus levocabastine nasal spray 0.05% in patients with moderate-to-severe allergic rhinitis. ORL J Otorhinolaryngol Relat Spec 2011;73:260-5.
  58. Berger W, Hampel F Jr., Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:375-81.
  59. Berger WE, White MV. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 2003;91:205-11.
  60. Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543-53.
  61. LaForce CF, Corren J, Wheeler WJ, Berger WE. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 2004;93:154-9.
  62. Penagos M, Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008;63:1280-91.
  63. Wu W, Walters RD, Nadeau GA, Botnick W, Broughton N. An integrated analysis of the efficacy of fluticasone furoate nasal spray versus placebo on the nasal symptoms of perennial allergic rhinitis. Allergy Asthma Proc 2013;34:283-91.
  64. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 2003;117:843-5.
  65. Naclerio RM. Allergic rhinitis. N Engl J Med 1991;325:860-9.
  66. Howarth PH. Cromoglycate. In: Mygind N, Naclerio RM, editors. Allergic and non-allergic rhinitis: Clinical aspects. Kopenhagen: Munksgaard, 1993.
  67. Middleton E Jr., Reed CE, Ellis EF, Adkinson NF Jr., Yunginger JW, Busse WW. Allergy. In: Principles and practice. St. Louis: Mosby, 1993.
  68. Schuller DE, Selcow JE, Joos TH, Hannaway PJ, Hirsch SR, Schwartz HJ, et al. A multicenter trial of nedocromil sodium, 1% nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis. J Allergy Clin Immunol 1990;86:554-61.
  69. Bousquet J, Chanal I, Alquie MC, Charpin D, Didier A, Germouty J, et al. Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study. Allergy 1993;48:327-33.
  70. Fisher WG. Comparison of budesonide and disodium cromoglycate for the treatment of seasonal allergic rhinitis in children. Ann Allergy 1994;73:515-20.
  71. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987;62:125-34.
  72. Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1991;87:873-8.
  73. De Bruin ML, Van Puijenbroek EP, Egberts AC, Hoes AW, Leufkens HG. Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol 2002;53:370-4.
  74. Juel-Berg N, Darling P, Bolvig J, Foss-Skiftesvik MH, Halken S, Winther L, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: a systematic review and meta-analysis. Am J Rhinol Allergy 2017;31:19-28.
  75. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002;89:479-84.
  76. Mygind N. Glucocorticosteroids and rhinitis. Allergy 1993;48:476-90.
  77. Selner JC, Weber RW, Richmond GW, Stricker WE, Norton JD. Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Clin Ther 1995;17:1099-109.
  78. De Monchy JGR. Antihistaminica bij seizoengebonden allergische rinoconjunctivitis. Geneesmiddelen Bulletin 2002;36:39-45.
  79. Wang DY. Treatment of allergic rhinitis: H1-antihistamines and intranasal steroids. Curr Drug Targets Inflamm Allergy 2002;1:215-20.
  80. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9.e10.
  81. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. Mp29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33:324-32.
  82. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012;22:1-12.
  83. Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. Int Forum Allergy Rhinol 2015;5:95-103.
  84. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000;105:912-6.
  85. Allen DB, Meltzer EO, Lemanske RF Jr., Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407-13.
  86. Murphy K, Uryniak T, Simpson B, O›Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006;96:723-30.
  87. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22.
  88. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23.
  89. Behbehani AH, Owayed AF, Hijazi ZM, Eslah EA, Al-Jazzaf AM. Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Pediatr Ophthalmol Strabismus 2005;42:23-7.
  90. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, Arrieta-Gomez JR, Astorga del Toro R, Bravo-Escobar G. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004;130:187-91.
  91. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 2001;108:S54-8.
  92. Howland WC, 3rd, Dockhorn R, Gillman S, Gross GN, Hille D, Simpson B, et al. A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. J Allergy Clin Immunol 1996;98:32-8.
  93. Maspero JF, Rosenblut A, Finn A Jr., Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg 2008;138:30-7.
  94. Ozturk F, Yuceturk AV, Kurt E, Unlu HH, Ilker SS. Evaluation of intraocular pressure and cataract formation following the longterm use of nasal corticosteroids. Ear Nose Throat J 1998;77:846-8, 50-1.
  95. Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071-7.
  96. Teper A, Ratner PH. Mometasone furoate nasal spray is safe and effective for one-year treatment of children with perennial allergic rhinitis. J Allergy Clin Immunol 2008;121:S52-S3.
  97. Borum P, Gronborg H, Mygind N. Seasonal allergic rhinitis and depot injection of a corticosteroid. Evaluation of the efficacy of medication early and late in the season based on detailed symptom recording. Allergy 1987;42:26-32.
  98. Holmberg K, Karlsson G. Nasal polyps: medical or surgical management? Clin Exp Allergy 1996;26 Suppl 3:23-30.
  99. Ostergaard MS, Ostrem A, Soderstrom M. Hay fever and a single intramuscular injection of corticosteroid: a systematic review. Prim Care Respir J 2005;14:124-30.
  100. Aasbjerg K, Torp-Pedersen C, Vaag A, Backer V Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes. Respir Med 2013;107:1852-8.
  101. Baiardini I, Puggioni F, Menoni S, Boot JD, Diamant Z, Braido F, et al. Patient knowledge, perceptions, expectations and satisfaction on allergen-specific immunotherapy: a survey. Respir Med 2013;107:361-7.
  102. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med 2015;175:1301-9.
  103. Durham SR, Creticos PS, Nelson HS, Li Z, Kaur A, Meltzer EO, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol 2016;138:1081-8.e4.
  104. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy 2017;72:1597-631.
  105. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127.
  106. Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, et al. Clinical efficacy of 300ir 5-grass pollen sublingual tablet in a us study: the importance of allergen-specific serum ige. J Allergy Clin Immunol 2012;130:1327-34.e1.
  107. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-45.
  108. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117.
  109. Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, et al. Efficacy and safety of grass sublingual immunotherapy tablet, mk-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014;112:146-53.e2.
  110. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127.
  111. Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. Journal of Negative Results in BioMedicine 2013;12:10.
  112. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206-10.
  113. Durham SR, Walker SM, Varga EM, Jacobson MR, O’Brien F, Noble W, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-75.
  114. Eng PA, Reinhold M, Gnehm HP Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306-12.
  115. Norman PS, Van MT Jr. The safety of allergenic immunotherapy. J Allergy Clin Immunol 1990;85:522-5.
  116. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (it) and skin testing (st). J Allergy Clin Immunol 1987;79:660-77.
  117. Tomee JFC, Dubois AEJ. Allergeenimmunotherapie met inhalatieallergeenextracten. Jaren therapie, jaren profijt. Pharmaceutisch Weekblad 2005;9:301-4.
  118. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol 1990;85:473-9.
  119. Hallen H, Enerdal J, Graf P. Fluticasone propionate nasal spray is more effective and has a faster onset of action than placebo in treatment of rhinitis medicamentosa. Clin Exp Allergy 1997;27:552-8.
  120. Singh U, Bernstein JA, Haar L, Luther K, Jones WK. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. Am J Rhinol Allergy 2014;28:215-24.
  121. Banov CH, Lieberman P. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol 2001;86:28-35.
  122. Gehanno P, Deschamps E, Garay E, Baehre M, Garay RP Vasomotor rhinitis: clinical efficacy of azelastine nasal spray in comparison with placebo. ORL J Otorhinolaryngol Relat Spec 2001;63:76-81.
  123. Webb DR, Meltzer EO, Finn AF Jr., Rickard KA, Pepsin PJ, Westlund R, et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol 2002;88:385-90.
  124. Arikan OK, Koc C, Kendi T, Muluk NB, Ekici A. Ct assessment of the effect of fluticasone propionate aqueous nasal spray treatment on lower turbinate hypertrophy due to vasomotor rhinitis. Acta Otolaryngol 2006;126:37-42.
  125. Varricchio A, Capasso M, De Lucia A, Avvisati F, Varricchio AM, Bettoncelli G, et al. Intranasal flunisolide treatment in patients with non-allergic rhinitis. Int J Immunopathol Pharmacol 2011;24:401-9.
  126. Lundblad L, Sipila P, Farstad T, Drozdziewicz D. Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2001;121:505-9.
  127. Jacobs R, Lieberman P, Kent E, Silvey M, Locantore N, Philpot EE. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. Allergy Asthma Proc 2009;30:120-7.
  128. Georgitis JW, Banov C, Boggs PB, Dockhorn R, Grossman J, Tinkelman D, et al. Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life. Clin Exp Allergy 1994;24:1049-55.
  129. Bronsky EA, Druce H, Findlay SR, Hampel FC, Kaiser H, Ratner P, et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol 1995;95:1117-22.
  130. Druce HM, Spector SL, Fireman P, Kaiser H, Meltzer EO, Boggs P, et al. Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. Ann Allergy 1992;69:53-60.
  131. Karatzanis AD, Fragiadakis G, Moshandrea J, Zenk J, Iro H, Velegrakis GA. Septoplasty outcome in patients with and without allergic rhinitis. Rhinology 2009;47:444-9.
  132. Stewart MG, Smith TL, Weaver EM, Witsell DL, Yueh B, Hannley MT, et al. Outcomes after nasal septoplasty: results from the Nasal Obstruction Septoplasty Effectiveness (NOSE) study. Otolaryngol Head Neck Surg 2004;130:283-90.
  133. Ho WK, Yuen AP, Tang KC, Wei WI, Lam PK. Time course in the relief of nasal blockage after septal and turbinate surgery: a prospective study. Arch Otolaryngol Head Neck Surg 2004;130:324-8.
  134. Muhammad IA, Nabil-ur R. Complications of the surgery for deviated nasal septum. J Coll Physicians Surg Pak 2003;13:565-8.
  135. Blom HM, Van Rijswijk JB, Garrelds IM, Mulder PG, Timmermans T, Gerth Van Wijk R. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. Clin Exp Allergy 1997;27:796-801.
  136. Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom HM,
  137. Jose J, Coatesworth AP. Inferior turbinate surgery for nasal obstruction in allergic rhinitis after failed medical treatment. Cochrane Database Syst Rev 2010:Cd005235.
  138. Di Rienzo Businco L, Di Rienzo Businco A, Lauriello M. Comparative study on the effectiveness of coblation-assisted turbinoplasty in allergic rhinitis. Rhinology 2010;48:174-8.
  139. Di Rienzo Businco L, Di Rienzo Businco A, Ventura L, Laurino S, Lauriello M. Turbinoplasty with quantic molecular resonance in the treatment of persistent moderate-severe allergic rhinitis: comparative analysis of efficacy. Am J Rhinol Allergy 2014;28:164-8.
  140. Gunhan K, Unlu H, Yuceturk AV, Songu M. Intranasal steroids or radiofrequency turbinoplasty in persistent allergic rhinitis: effects on quality of life and objective parameters. Eur Arch Otorhinolaryngol 2011;268:845-50.
NHG-werkgroep:
Aalberse J, Fokkens W, Lucassen P, Sijbom M, Van Sleeuwen D, Wiersma T, Zegers R
3 gerelateerde lacunesGerelateerd onderzoek
E-mail